Overview: Methylation Status TestIntroduction: The Methylation Status Test assesses DNA methylation to diagnose cancers or genetic disorders, helping guide treatment for abnormal cell growth or developmental issues. Affecting 1 in 1,000 people with cancer, methylation changes pose diagnostic challenges due to epigenetic complexity. Following 2023 National Comprehensive Cancer Network (NCCN) guidelines, it uses bisulfite sequencing for high accuracy, supporting molecular pathology screening. This test is vital for diagnosis, therapy planning, and improving outcomes in oncology.
Other Names: DNA Methylation Test, Epigenetic Marker Assay.
FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.
Historical Milestone: Methylation testing began in the 1990s with research by Baylin, who linked it to cancer. Bisulfite sequencing advancements in the 2000s by Illumina improved detection, surpassing earlier methylation-specific PCR.
Purpose: Assesses DNA methylation patterns to diagnose cancers or genetic disorders, guides targeted therapy, and evaluates patients with developmental issues, aiming to manage disease.
Test Parameters: DNA methylation patterns
Pretest Condition: No special preparation required. Collect tissue or whole blood. Report history of cancer or genetic issues.
Specimen: Tissue (FFPE, 0.5-2 cma³), Whole Blood (EDTA, 3-5 mL); 4 mL whole blood in EDTA tube or tissue in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document cancer history or developmental issues. Include current medications or family history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., tumor growth), and sample collection risks.
Procedural Considerations: Uses bisulfite sequencing to assess methylation, requiring labs with sequencers. Results available in 5-7 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Abnormal patterns confirm cancer or disorder, guiding therapy. Early treatment might improve survival, while untreated cases lead to worsening. Normal patterns may require other tests.
Specialist Consultation: Consult an oncologist or geneticist for interpretation.
Additional Supporting Tests: Tumor markers, genetic panel, or imaging to confirm diagnosis.
Test Limitations: Specific to methylation; correlation with clinical status needed. False negatives possible with untested regions.
References: NCCN Guidelines, 2023; Cancer Research, Baylin SB, 2022.
